Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q2 2020 · 10-Q
Revenue$16.57M$16.57M+110.2% vs Q2 2019 Net Income-$33.76M-$33.76MN/M vs Q2 2019 EPS Diluted-$0.91-$0.91N/M vs Q2 2019 Operating Income-$41,833,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$24,774,000N/M Margins · derivedOperating margin-252.5%+215.3 pt vs Q2 2019
Net margin-203.8%−185.3 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 6, 2020 · 37 d after period end